| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Compared to type II sPLA2 (IC50 >10 μM), ASB14780 is more selective for cPLA2α (IC50 = 20 nM) [1]. With IC50 values of 0.54 μM and 0.64 μM, respectively, five minutes after stimulation, ASB14780 (preincubation for 30 minutes) suppresses cPLA2α in guinea pig whole blood (GWB) and human whole blood (HWB), with species-specific differences. Ca2+ ionophore A23187 at μM[1].
|
|---|---|
| ln Vivo |
Tetradecanoylphorbol acetate, or TPA, has the potential to produce acute ear inflammation that results in edema [1]. Tetradecanoylphorbol acetate (TPA) application in mice causes an increase in ear thickness, but ASB14780 (50 mg/kg; oral; once) inhibits this effect [1]. In a dose-dependent manner, ASB14780 (5 mg/kg; 20 mg/kg; oral; once daily) reduces AHR (airway hyperresponsiveness) and prevents LAR (late asthma response) and IAR (immediate asthma response) [1]. Based on the ratio of AUC after oral administration (10 mg/kg; po) and AUC after intravenous administration (1 mg/kg; iv), ASB14780 demonstrated good oral activity in mice, with an 89.6% oral activity [1]. Model F (%) AUC (h^μg/mL) Cmax (μg/mL) Mouse 89.6 7.12 5.12 Dog 34.3 17.1 4.96 Monkey 30.9 4.96 2.29 Note: Based on 10 mg/kg po dose data. Oral bioavailability and pharmacokinetic parameters of ASB14780 [1].
|
| Animal Protocol |
Animal/Disease Models: TPA (tetradecanoylphorbol acetate)-induced mouse ear edema model (female C57BL/6 mice) [1]
Doses: 50 mg/kg Route of Administration: po (oral gavage); TPA stimulation Results in the first 30 minutes: demonstrated high efficacy, inhibited ear swelling by 30%, and demonstrated anti-inflammatory activity in the body. Animal/Disease Models: Guinea pig ovalbumin (OVA)-induced asthma model [1] Doses: 5 mg/kg, 20 mg/kg Route of Administration: po (oral gavage); two single doses; 1 hour before and after passive sensitization administration Results 8 hrs (hrs (hours)) after dosing: Inhibition of IAR (immediate asthma response) and LAR (late asthma response) in a dose-dependent manner. |
| References |
| Molecular Formula |
C35H38N2O6
|
|---|---|
| Molecular Weight |
582.686029911041
|
| Exact Mass |
582.273
|
| CAS # |
1069046-00-9
|
| PubChem CID |
68519061
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
43
|
| Complexity |
702
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MBPXGBINIINSEU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H27NO3.C4H11NO3/c33-31(34)20-13-24-12-19-30-29(21-24)25(14-11-23-7-3-1-4-8-23)22-32(30)26-15-17-28(18-16-26)35-27-9-5-2-6-10-27;5-4(1-6,2-7)3-8/h1-10,12,15-19,21-22H,11,13-14,20H2,(H,33,34);6-8H,1-3,5H2
|
| Chemical Name |
2-amino-2-(hydroxymethyl)propane-1,3-diol;3-[1-(4-phenoxyphenyl)-3-(2-phenylethyl)indol-5-yl]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7162 mL | 8.5809 mL | 17.1618 mL | |
| 5 mM | 0.3432 mL | 1.7162 mL | 3.4324 mL | |
| 10 mM | 0.1716 mL | 0.8581 mL | 1.7162 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
